Skip to main content

Oral delivery of vaccine and therapeutic products using non-pathogenic lactic acid bacteria

Objective

Scientific discoveries made in previous EC funded research programs on the lactic acid bacteria (LAB) have shown that there is considerable potential to develop products based on the oral delivery of vaccine and therapeutic agents using harmless commensally LAB. The aim is to harness this potential by developing and testing prototype LAB-based products for vaccination, prevention and treatment of type I allergy, treatment of a metabolic disorder and delivery of a therapeutic antioxidant. This multifaceted strategy for exploitation is underpinned by research on LAB fermentation and technological innovations that will enhance the efficiency of LAB delivery systems.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

INSTITUTE OF FOOD RESEARCH
Address
Norwich Research Park, Colney
NR4 7UA Norwich
United Kingdom

Participants (8)

BIONEER AS
Denmark
Address
Kogle Alle, 2
2970 Hoersholm
INSTITUT PASTEUR DE LILLE
France
Address
1,Rue Du Professeur Calmette 1
59019 Lille
INSTITUTE OF MICROBIOLOGY - ACADEMY OF SCIENCES OF THE CZECH REPUBLIC
Czechia
Address
Videnska 1083
14220 Praha 4
NILAB APS
Denmark
Address
Toftegaardvej 16
5500 Middelfart
PROVALIS UK LTD
United Kingdom
Address
Newtech Square, Deeside Industrial Park
CH5 2NT Deeside
UNIVERSITE CATHOLIQUE DE LOUVAIN
Belgium
Address
Croix Du Sud 5
1348 Louvain-la-neuve
UNIVERSITY OF VIENNA
Austria
Address
Waehringer Guertei 18-20
1090 Wien
WAGENINGEN CENTRE FOR FOOD SCIENCES
Netherlands
Address
Kernhemseweg 2
6710 BA Ede Gld